At DERM 2025, AbbVie presented results from two open-label extension studies evaluating risankizumab (Skyrizi) in difficult-to-treat psoriasis locations: the scalp and genital regions. In patients with moderate-to-severe genital PsO, 80% achieved clear or almost clear scores (sPGA-G) at Week 52. In the scalp cohort, 90% achieved PSSI 90 at one year, with rapid onset evident by Week 4. These regions, often excluded from pivotal trials, are critical for quality of life due to high sensitivity and stigma. The studies reported no new safety signals and had low discontinuation rates. Patients also reported improved sexual health and social confidence metrics. These findings reinforce Skyrizi’s high skin clearance capacity, even in challenging anatomical regions, and may inform future guideline updates on location-specific treatment needs.

Citation: https://news.abbvie.com/news/press-releases/skyrizi-delivers-1-year-skin-clearance-in-scalp-and-genital-psoriasis-patients.htm

Implication: Data enhance Skyrizi’s utility in hard-to-treat areas, broadening its appeal to dermatologists and patients seeking rapid and visible relief.